News
TipRanks on MSN6h
Novo Nordisk’s Stock Soars Amid Strategic Moves
Novo Nordisk ( ($NVO) ) has risen by 10.44%. Read on to learn why. Novo Nordisk has seen a notable 10.44% increase in its stock price over the ...
The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...
The Print on MSN16h
India sees 20k bariatric surgeries a year. But blockbusters Mounjaro, Wegovy are shaking up obesity arena
India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...
Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...
When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback